Table 3 Prognostic factors by univariate and multivariate analyses

Gender

0.38

0.817 (0.521–1.281)

0.37

0.75 (0.406–1.402)

0.96

0.984 (0.508–1.907)

Age

0.70

1.005 (0.980–1.031)

0.03

0.97 (0.934–0.997)

0.03

1.049 (1.005–1.094)

ECOG

0.60

0.904 (0.622–1.313)

0.51

0.85 (0.521–1.385)

0.68

1.133 (0.627–2.050)

Tumor location

0.05

0.814 (0.661–1.001)

0.01

0.69 (0.518–0.905)

0.64

0.927 (0.671–1.279)

Clinical T stage

0.19

1.191 (0.919–1.543)

0.98

1.00 (0.714–1.414)

0.47

1.158 (0.775–1.730)

Clinical N stage

< 0.01

2.996(2.037–4.408)

0.00

2.68 (1.671–4.289)

< 0.01

2.495 (1.440–4.324)

< 0.01

2.465 (1.612–3.769)

< 0.01

2.293 (1.384–3.798)

< 0.01

2.418 (1.345–4.346)

Clinical M stage

< 0.01

2.142(1.463–3.136)

0.02

1.83 (1.094–3.046)

< 0.01

2.463 (1.391–4.362)

< 0.01

1.856 (1.268–2.716)

< 0.01

2.424 (1.358–4.238)

Clinical TNM stage

< 0.01

1.402(1.181–1.665)

0.03

1.29 (1.023–1.616)

< 0.01

1.487 (1.133–1.953)

Cycles of CC

0.95

0.990(0.719–1.365)

0.83

1.05 (0.682–1.608)

0.20

0.725 (0.442–1.187)

Regimen of CC

0.07

0.646(0.405–1.030)

0.87

0.94 (0.485–1.481)

0.63

1.235 (0.529–2.884)

Dose of GTV

0.51

1.000(0.999–1.000)

0.06

1.00 (0.999–1.000)

0.81

1.000 (0.999–1.001)

Dose of CTV

0.18

1.001(0.999–1.003)

0.78

1.00 (0.999–1.002)

0.70

1.000 (0.998–1.002)

Tumor response to CRT

< 0.01

1.691(1.389–2.060)

< 0.01

1.71 (1.315–2.228)

0.44

1.127 (0.834–1.524)

< 0.01

1.548 (1.262–1.899)

< 0.01

1.532 (1.162–2.021)

AC

0.74

0.971(0.819–1.152)

0.88

1.02 (0.809–1.281)

0.21

0.841 (0.643–1.100)